Table 1.
Target antigens for ADCs under development or in the clinic for cancer therapy [106].
| Indication | Targets |
|---|---|
| Acute myeloid leukaemia | CD25, CD33, CD123 (IL-3Rα), FLT3 |
| Breast cancer | CD25, CD174, CD197 (CCR7), CD205 (Ly75), CD228 (P79, SEMF), c-MET, CRIPTO, ErbB2 (HER2), ErbB3 (HER3), FLOR1 (FRα), Globo H, GPNMB, IGF-1R, integrin β-6, PTK7 (CCK4), nectin-4 (PVRL4), ROR2, SLC39A6 (LIV1A ZIP6) |
| Bladder cancer | CD25, CD205(Ly75) |
| Colorectal cancer | CD74, CD174, CD166, CD227 (MUC-1), CD326 (Epcam), CEACAM5, CRIPTO, FAP, ED-B, ErbB3 (HER3) |
| Gastric cancer | CD25, CD197 (CCR7), CD228 (P79, SEMF), FLOR1(FRα), Globo H, GRP20, GCC, SLC39A6 (LIV1A ZIP6) |
| Gliomas GIII and GIV | CD25, EGFR |
| Head and neck cancer | CD71 (transferrin R), CD197 (CCR7), EGFR, SLC39A6 (LIV1A ZIP6) |
| Hodgkin’s lymphoma | CD25, CD30, CD197 (CCR7) |
| Lung cancer | Axl, alpha v beta6, CD25, CD56, CD71 (transferrin R), CD228 (P79, SEMF), CD326, CRIPTO, EGFR, ErbB3 (HER3), FAP, Globo H, GD2, IGF-1R, integrin β-6, mesothelin, PTK7 (CCK4), ROR2, SLC34A2 (NaPi2b), SLC39A6 (LIV1A ZIP6) |
| Liver cancer | CD276 (B7-H3), c-MET |
| Melanoma | CD276 (B7-H3), GD2, GPNMB, ED-B, PMEL 17, endothelin B receptor |
| Mesothelioma | Mesothelin, CD228 (P79, SEMF) |
| Multiple Myeloma | CD38, CD46 (MCP), CD56, CD74, CD138, CD269 (BCMA), endothelin B receptor |
| Non-Hodgkin Lymphoma | CD19, CD20, CD22, CD25, CD30, CD37, CD70, CD71 (transferrin R), CD72, CD79, CD180, CD205 (Ly75), ROR1 |
| Ovarian cancer | CA125(MUC16), CD142 (TF), CD205 (Ly75), FLOR1(FRα), Globo H, mesothelin, PTK7 (CCK4) |
| Pancreatic cancer | CD25, CD71 (transferrin R), CD74, CD227 (MUC1), CD228 (P79, SEMF), GRP20, GCC, IGF-1R, integrin β-6, nectin-4 (PVRL4), SLC34A2 (NaPi2b), SLC44A4, alpha v beta6, mesothelin |
| Prostate cancer | CD46 (MCP), PSMA, STEAP-1, SLC44A4, TENB2 |
| Renal cancer | AGS-16, EGFR, c-MET, CAIX, CD70, FLOR1 (FRα) |